BMY Jan 2025 57.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:28PM EDT. Market open.
| Previous close | 0.5900 |
| Open | 0.6700 |
| Bid | 0.6200 |
| Ask | 0.6600 |
| Strike | 57.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.6200 - 0.6900 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.36k |
Simply Wall St.Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Bristol-Myers Squibb ( NYSE:BMY ) First Quarter 2024 Results Key Financial Results Revenue: US$11.9b (up 4.7% from 1Q...
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Business WireCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
© 2024 Yahoo. All rights reserved.